Hide metadata

dc.date.accessioned2021-08-28T15:14:03Z
dc.date.available2021-08-28T15:14:03Z
dc.date.created2021-06-23T16:10:39Z
dc.date.issued2021
dc.identifier.citationAmundsen, Siri Nordeng, Hedvig Nordeng, Hedvig Marie Egeland Fuskevåg, Ole Martin Nordmo, Elisabet Nordmo, Elisabet N Sager, Georg Spigset, Olav . Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding. Basic & Clinical Pharmacology & Toxicology. 2021, 128(6), 1-10
dc.identifier.urihttp://hdl.handle.net/10852/87420
dc.description.abstractClinical data on the transfer of triptans into human breast milk remain scarce. In a lactation study including 19 breastfeeding women with migraine, we examined the excretion of six different triptans into milk. Following intake of a single dose, each participant collected seven breast milk samples at predefined intervals up to 24 hours after dose. Triptan concentrations in milk were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Infant drug exposure was estimated by calculating the relative infant dose (RID). Twenty-two breast milk sample sets were obtained for sumatriptan (n = 8), rizatriptan (n = 5), zolmitriptan (n = 4), eletriptan (n = 3), almotriptan (n = 1) and naratriptan (n = 1). Based on the average concentration in milk throughout the day, estimated mean RIDs (with range in parenthesis) were as follows: eletriptan 0.6% (0.3%-0.8%), sumatriptan 0.7% (0.2%-1.8%), rizatriptan 0.9% (0.3%-1.4%), almotriptan 1.8% (-), zolmitriptan 2.1% (0.7%-5.3%) and naratriptan 5.0% (-). Infant drug exposure through breastfeeding appears to be low and indicates that use of the triptans in this study is compatible with breastfeeding. Naratriptan may not be first choice in breastfeeding mothers initiating triptans during the neonatal period.
dc.languageEN
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.titleTransfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding
dc.typeJournal article
dc.creator.authorAmundsen, Siri
dc.creator.authorNordeng, Hedvig
dc.creator.authorNordeng, Hedvig Marie Egeland
dc.creator.authorFuskevåg, Ole Martin
dc.creator.authorNordmo, Elisabet
dc.creator.authorNordmo, Elisabet N
dc.creator.authorSager, Georg
dc.creator.authorSpigset, Olav
cristin.unitcode185,0,0,0
cristin.unitnameUniversitetet i Oslo
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1918022
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Basic & Clinical Pharmacology & Toxicology&rft.volume=128&rft.spage=1&rft.date=2021
dc.identifier.jtitleBasic & Clinical Pharmacology & Toxicology
dc.identifier.volume128
dc.identifier.issue6
dc.identifier.startpage795
dc.identifier.endpage804
dc.identifier.doihttps://doi.org/10.1111/bcpt.13579
dc.identifier.urnURN:NBN:no-90054
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1742-7835
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/87420/1/Amundsen%2B2021%2Bbcpt.13579.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial 4.0 International
This item's license is: Attribution-NonCommercial 4.0 International